[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001772:Blood Cell Count; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002819:Chorea; D003248:Constipation / Q000139:chemically induced; D003891:Desipramine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D012156:Reticulocytes / Q000503:physiopathology; D014839:Vomiting / Q000139:chemically induced
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D003891:Desipramine
Thérapeutique du syndrome de Parkinson par la L-Dopa "per os" associée à un inhibiteur de la décarbosylase (Ro IV 46.02)